The Global Auto-immune hemolytic anemia drugs market size stood at USD 615 million in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Autoimmune hemolytic anemia (AHA) is also called immune hemolytic anemia. It is an immune and rare red blood cell disorder. Autoimmune hemolytic anemia occurs when the immune system makes antibodies that attack red blood cells in the body. This decreases the number of red blood cells, resulting to hemolytic anemia. Common symptoms of autoimmune hemolytic anemia include breathing difficulties, dark urine and/or splenomegaly, jaundice, and weakness & fatigue with tachycardia
The global autoimmune hemolytic anemia therapeutics market is primarily driven by increase in the use of drugs such as corticosteroids for patients with autoimmune hemolytic anemia. Corticosteroids are highly preferred to minimize complications such as osteoporosis, diabetes, obesity, and uncontrolled hypertension
Limited number of drugs are available for autoimmune hemolytic anemia treatment. This has encouraged biotechnology researchers and pharmaceutical companies to invest in research & development to develop novel therapies such as parsaclisib and fostamatinib
Additionally, rise in demand for the development of combination therapies and anemia therapeutics in patient assistance programs is expected to drive the global autoimmune hemolytic anemia therapeutics market